Literature DB >> 16830244

[Therapy options of advanced laryngeal carcinomas with regard to the quality of life of the patients].

Elke Hayn1, Martin Burian, Johannes Gobertus Meran.   

Abstract

Advanced laryngeal carcinomas are in most cases still associated with a very poor prognosis and highly reduced quality of life. This case report shows the various and severe complications that occurred after a total laryngectomy in spite of intensive medical treatment. Currently the development and introduction of new organ preserving procedures in advanced laryngeal cancer, without a loss of the prognostical outcome, represents one of the most up to date clinical oncological fields of research in head and neck cancer. This case report critically scrutinizes the current options of therapy available for patients suffering from advanced laryngeal carcinomas, as it is essential in the author's opinion that the decision on treatment is made within the scope of an intensive interdisciplinary strategy of therapy, and is reached by including all possible options available in order to achieve the best possible quality of life for the patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16830244     DOI: 10.1007/s10354-006-0287-4

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  14 in total

1.  Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer.

Authors:  C A Mantz; E E Vokes; K Stenson; M S Kies; B Mittal; M E Witt; M A List; R R Weichselbaum; D J Haraf
Journal:  Cancer J       Date:  2001 Mar-Apr       Impact factor: 3.360

2.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

Review 3.  The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer.

Authors:  E E Vokes; D J Haraf; M S Kies
Journal:  Semin Oncol       Date:  2000-08       Impact factor: 4.929

Review 4.  Current options in management of head and neck cancer patients.

Authors:  A J Correa; B B Burkey
Journal:  Med Clin North Am       Date:  1999-01       Impact factor: 5.456

5.  Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial.

Authors:  J C Horiot; P Bontemps; W van den Bogaert; R Le Fur; D van den Weijngaert; M Bolla; J Bernier; A Lusinchi; M Stuschke; J Lopez-Torrecilla; A C Begg; M Pierart; L Collette
Journal:  Radiother Oncol       Date:  1997-08       Impact factor: 6.280

6.  Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer.

Authors:  C A Mantz; E E Vokes; M S Kies; B Mittal; M E Witt; M A List; R R Weichselbaum; D J Haraf
Journal:  Ann Oncol       Date:  2001-03       Impact factor: 32.976

7.  Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.

Authors:  M S Kies; D J Haraf; I Athanasiadis; M Kozloff; B Mittal; H Pelzer; A W Rademaker; B Wenig; R R Weichselbaum; E E Vokes
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

8.  Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.

Authors:  A Psyrri; M Kwong; S DiStasio; L Lekakis; M Kassar; C Sasaki; L D Wilson; B G Haffty; Y H Son; D A Ross; P M Weinberger; G G Chung; D Zelterman; B A Burtness; D L Cooper
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

9.  mTHPC-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 patients.

Authors:  Anil K D'Cruz; Martin H Robinson; Merrill A Biel
Journal:  Head Neck       Date:  2004-03       Impact factor: 3.147

10.  [Controlled clinical trials of hyperfractionated and accelerated radiotherapy in otorhinolaryngologic cancers].

Authors:  J C Horiot
Journal:  Bull Acad Natl Med       Date:  1998       Impact factor: 0.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.